The Business of Pharmacy: How to Amp Up Your Growth Journey

OBJECTIVES



Highlight the importance of operational 'fitness' in growing your business



Understand the role 'organizing' has in accelerating growth



Examine the impact Pharmacy has on care models, and enhancing health care delivery




Explore the challenges in access to health care, and how Pharmacy help organizations overcome this current challenge

Concern grows around US health-care workforce shortage: 'We don't have enough doctors'

By Jacqueline Howard, CNN © 5 minute read · Published 11:00 AM EDT, Tue May 16, 2023 A X 🖬 👁

340B contract pharmacy arrangements

STATUS OF US HEALTH



Could contentious payer-provider negotiations become the post-**COVID norm?**

() Mar 12, 2024 - 03:20 PM

Elevance Health (Anthem)

By Paige Minemyer · Sep 13, 2023 4:00pm

Bon Secours Health System

A flagpole at Cigna Corp.'s headquarters in Bloomfield, Connecticut. Photographer: Michael Nagle/Bloomberg

American Hospital Association*	AHA Member 0	Center About Pres	s Center AHA Help	Center Register / I	Log In	Search AHA
Advancing Health in America	Advocacy ~	Career Resources ~	Data & Insights ~	Education & Events ~	News ~	Individuals & Communities ~

Fitch and S&P maintain gloomy outlook for not-for-profit hospital sector in 2024

Image: https://www.bloomberg.com/news/articles/2023-08-22/drug-price-negotiations-enrich-pharmacy-benefit-managers; https://www.aha.org/news/headline/2024-01-05-fitch-and-sp-maintain-gloomy-outlook-not-profit-hospital-sector-2024; https://www.fiercehealthcare.com/payers/could-contentious-payer-provider-negotiations-become-norm; https://www.cnn.com/2023/05/16/health/health-care-worker-shortage/index.html:

https://www.aha.org/news/headline/2024-03-12-urged-aha-8th-circuit-upholds-arkansas-law-protecting-340b-contract-pharmacy-arrangements; https://www.cnn.com/2023/08/10/health/drug-shortage-pharmacist-survey/index.html



Register / Log li

Nearly all hospital pharmacists say drug shortages are negatively impacting care; a third say impacts are 'critical'

By Deidre McPhillips, CNN 3 minute read - Published 10:02 AM EDT, Thu August 10, 2023 AXIO




than 300 drugs in the US, according to data from the University of chemotherapy drugs are among the most affected. Gern




SIGNIFICANT GROWTH (CONTINUES) ON THE NEAR

HRI projects medical cost trend to be 7.0% in 2024, up from 6.0% in 2023

Group Group/Individual



By 2027, estimated profit pools for government segments will be about 65 percent larger than commercial segments driven by accelerated Medicare Advantage penetration.




COST MANAGEMENT: NOT GLAMOROUS, YET IMPACTFUL

		Healthcare Provider Current Situation	Reimbursement or Revenue Initiative	Cost Management Initiative	
	Revenue	\$500,000	\$1,000,000	\$500,000	GPO, Direct Sourcing, Inventory Mgmt Soln,
	Cost	\$475,000 95%	\$950,000 95%	\$450,000 90%	
	Profit	\$25,000 5%	\$50,000 5%	\$50,000 10%	
ļ		To increase profitability by \$25M, you could either	Increase revenue 100%	- OR Reduce costs 5% -	20 times the cost reduction nee

eded!

Distribution of projected healthcare EBITDA across the pharma value chain (illustrative),¹ 2027, \$ billion

NOTEWORTHY WHERE THE GROWTH IS OCCURRING



Source: Trends in Prescription Drug Launch Prices, 2008-2021

PBM/PA non-dise	Retail-based specialty pharmacy Hospital specialty pharmacy managed services ⁴ Home infusion	Pharmaceutical distributors/ wholesalers	Mail
	Hospital-owned specialty pharmacy		Retail
	Physician office/ambulatory site infusion		
	Hospital outpatient infusion		
	Central fill specialty pharmacy		
12	38	10	10
Pharmacy benefit	Specialty pharmacy and infusion services	Distributor/	Traditional
manager/ administrator ²		wholesaler	dispensers ³

'Sub-segment numbers may not sum to segment totals due to rounding.

*Excludes profit earned by PBM-owned specialty pharmacies and mail pharmacies, which is captured under central fill specialty pharmacy and mail respectively. *Excludes specialty pharmacy (specialty dispensed through retail channels is captured under retail-based specialty pharmacy).


*Specialty pharmacy services outsourced to vendors such as Shields/Trellis.

Source: McKinsey Profit Pools Model

2022-2027 growth rate, %

<0 0-5 5-10 >10

VALUE OF CONSOLIDATED SERVICE



https://www.hpnonline.com/sourcing-logistics/article/13002079/consolidated-service-centers-a-viable-strategy and the service of the service

POTENTIAL VALUE IN CENTRALIZED SERVICE FACILITY **RELATED TO COST OF RELATED TO OVERHEAD** GOODS

entory Shrinkage	(Consolidated) Sourcing savings	Overhead i.e., moving from limited, more expensive on-campus footprint	Replace manual processes through automation and increase usage of technology
mize drug shortage nanagement (to eserve clinic/OR encounters)	In-source / Organize from third-party providers (i.e., repackaging, 503B)	Streamline delivery from a centralized location	Contract labor

Inventory

Optimize c

manaa preserve

UNC HEALTH CONSOLIDATED SERVICE FACILITY 'FIRST GENERATION'

Located 'off-site'

Multi-Department Facility

Developed over 10+ years old

Completely occupied through expansion of Departments and services in that time

Pharmacy = 15k sq ft



POTENTIAL SERVICES AT A CENTRALIZED SERVICE FACILITY

Distribution Services

- Central ADM Replenishment
- Tray Replenishment
- Clinic Replenishment
- Unit dose Packaging (repackaging)
- Low Unit of Measure Distribution
- Bulk / strategic buys


Compounding Services


- IV admixture (503A)
- IV compounding (503B)
- Sterilization (USP) services

DECTRICTER

PHARMACY SCM: CREATE A COMPELLING VALUE PROPOSITION

Focus on cost management > revenue increase





OTHER OUTCOME S FROM CONSOLID ATED SERVICE CENTER

Business Continuity

- Strategic Redundance
- Higher oversight on distributive business

<u>Quality/Safety</u>

- Standardize workflows
- Technology directed picking

Customer Experience

 Consolidate vendor mgmt

KEY LEARNINGS 'FIRST GENERATION'

Challenges with multi-department building management

Building type i.e., warehouse vs. flex vs. office space

Office space?

Fixed capital items v. allocated space, and its impact on workflows

Distribution of projected healthcare EBITDA across the pharma value chain (illustrative),¹ 2027, \$ billion



CHALLENGES OF EXPONENTIA L OUTPATIENT GROWTH

PBM/PBA non-dispa	Retail-based specialty pharmacy Hospital specialty pharmacy managed services ⁴ Home infusion	Pharmaceutical distributors/ wholesalers	Mail
	Hospital-owned specialty pharmacy Physician office/ambulatory site infusion Hospital outpatient infusion		Retail
	Central fill specialty pharmacy		
12	38	10	10
Pharmacy benefit manager/ administrator ²	Specialty pharmacy and infusion services	Distributor/ wholesaler	Traditional dispensers ³

'Sub-segment numbers may not sum to segment totals due to rounding.


^aExcludes profit earned by PBM-owned specialty pharmacies and mail pharmacies, which is captured under central fill specialty pharmacy and mail respectively. ^aExcludes specialty pharmacy (specialty dispensed through retail channels is captured under retail-based specialty pharmacy).

*Specialty pharmacy services outsourced to vendors such as Shields/Trellis.

Source: McKinsey Profit Pools Model


EXPONENTIAL GROWTH IN HIGH-VOLUME PHARMACY HAS CHALLENGED OPERATIONIAL CAPACITY

High-Volume Pharmacy Script Count: FY20 to FY22











BD

15

Headwinds

- Operational bottlenecks
- •Labor challenges
- Technology challenges
- •Manual workarounds

Tailwinds

•Internal volume growth


•Executive / physician engagement (although not organized)

•COVID / Post-COVID drive for mail

Market growth


•Growth (internal) PBM business

CHALLENGED TO MANAGE EXTERNAL STAKEHOLDER 'WANTS' IN STRATEGIC PLANNING PROCESS



Impact

CHALLENGED TO MANAGE INTERNAL 'WANTS' IN THE



KEY BUSINESS ACTIONS ('GET ORGANIZED')

- 1. Coordinated RFP for automation solution
- 2. Completing 'needs assessment' for operational space, equipment, etc
- 3. Using 'needs assessment' to identify real estate and complete design phase
- 4. Organizing internal / external 'asks' through the vehicle of an executive steering committee + work group

ORGANIZING FOR SUCCESS

Launch RFP in Fall 2021 for High-Volume Automation Solution (COMPLETE Fall 2022) Launched real estate assessment in Spring 2022 (COMPLETE Fall 2022)

Launch Steering Committee to organize growth Fall 2022

+ Work group to move project along

Built Pro-Forma (RFP + Real Estate + Initiatives from WG) (COMPLETE Spring 2023)

Capital Ask made Spring 2023 (FUNDED Summer 2023)


Site Ready (Planned for Spring 2024)


Go-Live (Planned for Fall 2024)

BD


ASHP CENTRALIZED SHARED SERVICES SURVEY - 2021

Health Systems with a Centralized Shared Service Facility (CSSF) (n=70)





ASHP CENTRALIZED SHARED SERVICES SURVEY - 2021



CONCEPT IS GAINING STEAM!

SUPPLY CHAIN February 29, 2024

New facility leverages unique partnership, technology to enhance AdventHealth's supply and resiliency strategy

Construction of \$40 million central pharmacy to begin under Baptist Health, Parata partnership

☑ February 13, 2023
 ☑ 968 Views

IU Health's new pharmacy hub aims to cut costs

Friday, July 28, 2023 03:03 PM EDT By John Russell, Indianapolis Business Journal

Henry Ford Health expects to save \$30M with new pharmacy warehouse

By Dustin Walsh

DECISIONS FOR 'SECOND GENERATION' FACILITY

What are current constraints on Organization's strategic advancement, and how could new CSF solve


Scale current services v. new diverse revenue streams

ROI on capital ask / diversification of revenues

Lease v. own AND new v. remodel site

Size?

UNC HEALTH CONSOLIDATE D PHARMACY CENTER SECOND GENERATION



LESSONS LEARNED

- •Utilize talent and expertise for informing the decision
- •Build workflows to inform technology and space needs
- •Be the expert in all aspects of the 'ask'
- •Ensure your story resonates with stakeholders
- •Understand the environment and opportunity/lack of
- •Assign talented, detailed leader as PM for project from start to finish

CLOSED LOOP STRATEGY

ACUTE CARE





Image: UNC Internal Slide


EXAMPLE SPECIALTY PHARMACY WORKFLOW -C CTVLE **PREVIO Full UNCH**



Partial UNCH

No UNCH

EXAMPLE SPECIALTY PHARMACY WORKFLOW –




STORY

New model for patients receiving new drug, Venetoclax

However, there were clinical risks with this drug historically requiring inpatient stay + coordination of care (insurance verification/financial assistance)

A pharmacist practitioner led program, initiated in the outpatient setting, included:
In-house medication assistance program (MAP)
In-house specialty pharmacy (SP)
Other interdisciplinary team members




SAFETY

Total 82 patients included in the study, with 47 (57%) started outpatient

39 of the 47 outpatients (83%) were able to remain outpatient for entirety of first 7 days

Rate of tumor lysis syndrome within 7 days of outpatient initiation was low



Pelcovits, A., Moore, J., Bakow, B. et al Support Care Cancer (2021). https://doi.org/10.1007/s00520-021-06119-7 Keruakous A, Saleem R, Asch A. Journal of Clinical Oncology 2020 38:15_suppl, e19542-e19542 Apel A, Moshe Y, Ofran Y, et al. *Am J Hematol*. 2021;96(7):790-795 Feld J, Tremblay D, Dougherty M, et al. *HemaSphere*. 2021;5(4):e549

EFFICIENCY AND PATIENT COST SAVINGS

The median time to venetoclax access (including prior authorization and copay assistance) was **3 days** (range: 0 – 37 days)

72% of included outpatients were eligible and required copay assistance

Estimated **\$2,130,645*** secured in drug financial assistance for outpatient AML-venetoclax during this time frame

*For those receiving manufacturer assistance, cost savings estimated based on AWP venetoclax pricing for 1 year Mitchell A, Muluneh B, Patel R, Basch E. J Oncol Pharm Pract. 2018;24(6):424-432.

HEALTHCARE SYSTEM COST SAVINGS

Estimated daily AML inpatient cost	\$3,300/day
Estimated hospital days saved (no hospitalizations in first week, n = 39)	273 days
Estimated hospitalization cost avoidance over study period	\$900,900
Estimated cost of week 1 of venetoclax (AWP)	\$2,969
Estimated drug cost avoidance (n=39) over study period	\$115,791
Total estimated cost avoidance over study period	<u>\$1,016,691</u>


Roemer, M. Cancer-Related Hospitalizations for Adults – 2017. Statistical Brief #270. Agency for Healthcare Research and Quality. https://www.hcup-us.ahrq.gov/reports/statbriefs/sb270-Cancer-Hospitalizations-Adults-2017.pdf

LESSONS LEARNED

- •Healthcare is changing, and we must adapt to the external forces
- •An integrated health system (an its electronic health record) can offer a best practice in health care deliver
- •Electronic health care record is a key collaborator within health care providers
- •When launching new services, you should evaluate the impact on the triple aim
- •Utilize success to further growth of your service offerings

RECENT CHALLENGES IN PATIENT ACCESS

Status of State Action on the Medicaid Expansion Decision




Introducing a new Specialty Pharmacy program, Free Market Health

August 01, 2023

Pharmacy

Blue Cross and Blue Shield of North Carolina (Blue Cross NC) is introducing a new marketbased program with Free Market Health (FMH) to help our members get certain covered specialty prescriptions at a lower cost. In an effort to keep health care as affordable as possible, the program will provide an automated system to compare and choose the best fit Blue Cross NC-contracted specialty pharmacy to provide our members' specialty drugs at the lowest cost possible.

The program launches on October 1, 2023, for fully-insured commercial members and will include a subset of specialty medications that Blue Cross NC covers today, including medications used to treat multiple sclerosis, rheumatoid arthritis, cancer and more.




THROUGHPUT CHALLENGE AND ED WAIT TIMES

- Higher volumes of patients seeking care
- Backlog in primary care providers
- Surging volumes in ED and into overflow
- Acuity seems to be climbing
- Delays in discharge (increasing length of stay impacting critical metrics)
- Opportunity for pharmacy to support discharges as a key cog in throughput

Median time, in hours, patients spent in hospital emergency rooms in North Carolina

12-month average as of Q3 of each year; 2014–2022




Data: Centers for Medicare and Medicaid Services; Note: Medians include Veterans Health Administration and Department of Defense hospital data; Chart: Jacque Schrag and Alice Feng/Axios

THE CHALLENGE

Focus on throughput (discharges):

- Creating capacity
- Providing optimal patient experience
- Supporting providers and staff

Goal Statement: Increase the efficiency and timeliness of patient flow processes to allow more patients to be safely discharged, which creates space for more patients who need hospital-level care.



Key: Blue arrows: Flow within hospital | Red arrows: Flow into hospital | Green arrows: Flow out of hospital | Width of arrows: Typical flow volumes

Lag Measure: Decrease TAT from discharge order to bed ready, from 267 minutes to 245 minutes (8.5%) by 03/31/2023.

	Lead Measure (Veekly)										
	Patient Tran	sport response	to DIC requests	Use of Sta Assigned (SVAT	Territory	to impro	ssignments ve room iness	with TAT <	prescriptions 1 hour (goal: ≥ 0%)	Increase us noon	e of DHC by (daily)
Date (week ending)	Actual (average/me dian, in	farget (mins	Total Trips	Actual	Target	Actual	Target	Actual	Target	Actual	Target
7/3/2022	30	20	287		50	66	60	75%	80%	4	11
7/10/2022	35	20	239		50	66	60	75%	80%	3	11
7/17/2022	35	20	259	1	50	65	60	75%	80%	3	11
7/24/2022	28	20	249		50	69	60	75%	80%	2	11
7/31/2022	31	20	286	(50	62	60	74%	80%	4	11
8/7/2022	32	20	284	31	50	60	60	76%	80%	16	11
8/14/2022	32	20	281	53	50	60	60	62%	80%	7	11
8/21/2022	31/28	20	276	63	50	64	60	61%	80%	13	11
8/28/2022	29/24	20	267	59	50	59	60	74%	80%	10	11
9/4/2022	23720	20	271	60	50	58	60	78%	80%	8	11
9/11/2022	25721	20	268	42	50	63	60	76%	80%	6	11
9/18/2022	34731	20	299	73	50	57	60	80%	80%	15	11
9/25/2022	28/25	20	273	62	50	62	60	75%	80%	12	11
10/2/2022	25721	20	275	51	50	63	60	84%	80%	7	11
10/9/2022	27/24	20	299	73	50	62	60	89%	80%	5	11
10/16/2022	26722	20	269	59	50	60	60	87%	80%	12	11
10/23/2022	34731	20	274	63	50	59	60	87%	80%	10	11
10/30/2022	35729	20	270	55	50	59	60	84%	80%	9	11

	JUL	AUG	SEP	OCT	NOV	DEC	JAN	FEB	MAR	APR	MAY	JUN
Actual	264	255	257	264	256	256	256	264	262	271	258	
Target	245	245	245	245	245	245	245	245	245	245	245	245

Wins & Accomplishments - TAT Goal MET week ending 5/14/2023 (245 minutes) - EVS- Almost back to goal (61) with # of internal movements lower compared to # of D/Cs - EVS - Loosing 4 Employees due to promotions or lateral movement within UNC and 1 due to PDC - Pharmacy working with Pt. Relations and Mktg. on DHC/Pharmacy table card to be placed by EVS in clean and ready rooms (only question is who will be paying for the printing costs	Risks/Barriers - PLC Data Analyst moved to different dept. Sourcing replacement - LRC continues to be challenging as it relates to recruiting -	Items for Escalation & Proposed Solutions None at this time



Total Dispense Turnaround Time (Mins) 0-15 min 16-30 min 31-45 min 46-60 min 61-75 min 76-90 min 91-105 min 106-120 min >120 min Total 75 302 270 174 133 46 24 41 26 7% 28% 25% 16% 12% 4% 2% 4% 2% Increment % 75% 92% Cumulative % 7% 35% 59% 87% 94% 98% 100% COP Discharge Prescription Turnaround Time - All Same Day Scripts (< 4 hours) - Week of 7/24/22 100% 98% 100% 30% 94% 92% 87% 90% 25% 80% 75% 70% 20% 59% 60% Incremental % %51 50% ā 40% 35% 10% 30% 20% 5% 10% 28% 25% 16% 12% 4% 2% 4% 7% 0% 0% 0-15 min 16-30 min 31-45 min 46-60 min 61-75 min 76-90 min 91-105 min 106-120 min >120 min Increment % ——Cumulative %

GOAL: 80% OF DISCHARGE PRESCRIPTIONS ARE READY TO DISPENSE WITHIN 1 HOUR

WEEKLY HUDDLE REPORT OUT AND AUDIT OF OUTLIERS

MONTHLY REPORT OUT ON TRENDS AND FOLLOW UP

100% 9556 92% 50% 89% 187% 85% 50% 87%87% 87% 87% 87% 86% 85% 82% 80% BD% **START** BD% 783 76% 75%75%75% 75% 70% 65% 60% 55% BUTTER TIMPOT TRATER THEOR TROPORT TRATON Actual ····Linear(Actual)

Discharge Prescriptions with Turnaround Time ≤ 1 hour (goal: ≥ 80%)

KEY LEARNING WAS UPSTREAM IMPACT ON **PROVIDERS FOR** PRIOR **AUTHORIZATION** REQUIREMENTS

Table 1: Measures of Success				
Metric	Value			
Approval rate	81%			
Estimated potential margin on all approved medications if dispensed from a UNC Health Outpatient Pharmacy (including SSC)	\$47,000			
Estimated margin on all prescriptions <i>dispensed</i> from UNC Health Outpatient Pharmacy (including SSC)	\$17,600			
Average patient copay	\$54			
Median copay	\$4			

Table 2: Time Valuation: Investment and ROI per Prior Authorization Attempt (38 min)

Role	Labor Investment (salary + benefits)	ROI* (est. margin \$1,175/approved rx)
Pharmacy Access & Solutions Technician	\$18.70	44.0
Physician, Resident	\$25.67	32.0
Clinical Nurse-II	\$30.68	26.8
Pharmacist	\$49.22	16.7
Physician, Attending	\$47.50	13.9
* ROI accounts for 70% approval rate prior to discharge		

LESSONS LEARNED

- •Recognize health care workflows are often dependent on multiple teams working in unison
- •Pharmacy may be a bottleneck in a care workflow
- •Appreciate how pharmacy support the 'challenge' and understand your limitations on meeting the challenge
- •Utilize an opportunity to advance pharmacy services

CONCLUSION

- Pharmacy is best informed to understand the medication use process, and to ensure operational excellence in those workflows
- Organizing through prioritization and collaboration can optimize the end outcome
- There are key opportunities for Pharmacy to engage in care redesign and offer solutions to national challenges
- Access to health care is a problem throughout the United States, and Pharmacy offers an available discipline who can support care access

The Business of Pharmacy: How to Amp Up Your Growth Journey